Broad

Societal CDMO Enters Into Definitive Agreement to be Acquired by CoreRx, Inc.

Retrieved on: 
Wednesday, February 28, 2024
Broad, Society, CDMO, Commercial

CLEARWATER, Fla. and GAINESVILLE, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”) (Nasdaq: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has entered into a definitive agreement with CoreRx, Inc. (“CoreRx”) under which CoreRx will acquire Societal CDMO. CoreRx will commence a tender offer to acquire all outstanding shares of Societal CDMO for $1.10 per share in cash, subject to any applicable tax withholding. Societal CDMO’s board of directors unanimously approved the transaction and plans to recommend that all shareholders tender their shares in the tender offer.

Key Points: 
  • Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging
    CoreRx to Commence a Tender Offer for all Outstanding Shares of Societal CDMO, Inc.
    CLEARWATER, Fla. and GAINESVILLE, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”) (Nasdaq: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has entered into a definitive agreement with CoreRx, Inc. (“CoreRx”) under which CoreRx will acquire Societal CDMO.
  • CoreRx will commence a tender offer to acquire all outstanding shares of Societal CDMO for $1.10 per share in cash, subject to any applicable tax withholding.
  • Societal CDMO’s board of directors unanimously approved the transaction and plans to recommend that all shareholders tender their shares in the tender offer.
  • Raymond James & Associates, Inc. is acting as financial advisor to Societal CDMO.

Ultima Genomics to Launch UG 100™ System and Present Data at AGBT

Retrieved on: 
Monday, February 5, 2024
Biotechnology, Health, Genetics, Health Technology, Oncology, Flex, Genomics, Next wave, DNA, Ultima, Broad, Mass meeting, Harvard University, Regeneron Pharmaceuticals, Weill Cornell Medicine, Methylation, Lunch, Genome informatics, MIT, Physiology, Cancer, Genome, Antibiotics

Ultima Genomics, Inc. , a developer of a revolutionary new ultra-high throughput sequencing architecture, will present product and commercial launch details for the UG 100™ system as the Gold Sponsor at the Advances in Genome Biology and Technology (AGBT) General Meeting Feb. 5-8, 2024, in Orlando, FL.

Key Points: 
  • Ultima Genomics, Inc. , a developer of a revolutionary new ultra-high throughput sequencing architecture, will present product and commercial launch details for the UG 100™ system as the Gold Sponsor at the Advances in Genome Biology and Technology (AGBT) General Meeting Feb. 5-8, 2024, in Orlando, FL.
  • The Gold Sponsor workshop will also include presentations by customers and collaborators from multiple leading institutions including:
    Stacey Gabriel, Ph.D., Executive Vice President of Platforms and Scientific Execution, Institute Scientist, Broad Institute of MIT and Harvard
    Aziz Al’Khafaji, Ph.D., Associate Director, Technology Development – Genomics Platform, Broad Institute of MIT and Harvard
    Will Salerno, Ph.D., Executive Director of Genome Informatics & Data Engineering, Regeneron Pharmaceuticals
    Dan Landau, M.D., Ph.D., Professor of Physiology and Biophysics, Weill Cornell Medical College
    Join Ultima for a series of talks and poster sessions, including:
    Ultima Genomics will be hosting the Gold Sponsor Workshop and Lunch entitled “Genomics unleashed: the $100 genome and beyond” at 12:00 pm in Grand Sierra Ballroom D&E
    Ultima technology will be featured in three posters during the Tuesday poster session at 1:30 pm in Palms Ballroom I:
    101 - Advancing cancer genomics with cost-effective whole genome sequencing: somatic variant calling using the UG 100 platform,​ by Hila Benjamin of Ultima Genomics
    518 - A continued evaluation of the Ultima Genomics UG100 platform: operational advancements and new methods for ancient DNA, single-cell, and methylation applications, by Matthew Coole of the Broad Institute
    592 - Integration of mostly-natural sequencing by synthesis with multiple single cell and spatial assays: 10X Flex, Visium and immune profiling,​ by Gila Yanai of Ultima Genomics
    Ultima Genomics will be hosting a Technical Breakfast Workshop entitled “Introducing a New Era: Part Per Million Detection Accuracy with ppmSeq™️ Technology” at 8:00 am in Ultima Suite, Grand Sierra Ballroom C
    Ultima technology will be featured in three posters during the Wednesday poster session at 4:45 pm in Palms Ballroom I:
    557 - Assessment of Ultima Genomics $100 genome for whole genome sequencing-based cancer diagnostics, by Edwin Cuppen of the Hartwig Medical Foundation
    625 - Scalable Dual Indexed Single Cell WGS on Ultima Genomics, ​ by Andrew Wicks of the New York Genome Center​
    Ultima Genomics will be hosting a Technical Breakfast Workshop entitled “Introducing the Next Wave of Single Cell and Omics at Scale” at 8:00 am in Ultima Suite, Grand Sierra Ballroom C

Jaguar Gene Therapy Announces FDA Clearance of IND to Study JAG201 in a Genetic Form of Autism Spectrum Disorder and Phelan-McDermid Syndrome

Retrieved on: 
Wednesday, January 31, 2024
FDA, Other Health, Pharmaceutical, Managed Care, General Health, Biometrics, Mental Health, Infectious Diseases, Neurology, Genetics, Clinical Trials, Biotechnology, Science, Other Science, Research, Health, Parent, Synapse, Neuroscience, NHP, Mutation, Spectrum, Genetic disorder, Quality of life, Learning, PMSF, Memory, ASD, PMS, ICV, Investigational New Drug, Cognitive science, Broad, Prevalence, IND, Jaguar, Genetic testing, Frasier, SHANK3, ID, Spinal cord, Haploinsufficiency, DSM-IV codes, Gene therapy, Patient, Central nervous system, Harvard University, Speech, Food, Neuron, Disease, Communication, Risk, Sibling, Disorder, Psychiatry, 22q13 deletion syndrome, Intellectual disability, Broad Institute, MIT, Pediatrics, Pharmaceutical industry

Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) Application for JAG201, a gene therapy for a genetic form of autism spectrum disorder (ASD) and Phelan-McDermid syndrome (PMS).

Key Points: 
  • Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) Application for JAG201, a gene therapy for a genetic form of autism spectrum disorder (ASD) and Phelan-McDermid syndrome (PMS).
  • JAG201 aims to deliver functional SHANK3 via the AAV9 vector to treat the root cause of the disease.
  • “We are pleased to receive FDA clearance to bring our investigational SHANK3 gene therapy to the clinic.
  • The pre-clinical data indicate that JAG201 may have the potential to be transformative for those suffering with the disorder,” said Joe Nolan, chief executive officer of Jaguar Gene Therapy.

S2 Genomics Raises Series A Round Led by BroadOak Capital Partners and RCT

Retrieved on: 
Tuesday, January 23, 2024
Research, Medical Devices, Genetics, Health Technology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Genomics, Knowledge, RCT, The central science, Broad, Microscope

S2 Genomics, the leading manufacturer of tissue sample preparation systems for single cell genomics assays, announced today that it has raised $16 million in Series A funding from BroadOak Capital Partners and Research Corporation Technologies (RCT).

Key Points: 
  • S2 Genomics, the leading manufacturer of tissue sample preparation systems for single cell genomics assays, announced today that it has raised $16 million in Series A funding from BroadOak Capital Partners and Research Corporation Technologies (RCT).
  • Customers use suspensions of nuclei and high-viability cells produced by the Singulator to advance neuroscience and oncology research.
  • Additional funding will help us further grow our customer base and add new applications to the Singulator platform,” said Jonathan Schimmel, President and CEO of S2 Genomics.
  • "The Singulator platform tackles major scalability challenges in single cell genomics and makes it easier for new customers to access single cell applications."

Shearman & Sterling Releases its Annual Corporate Governance & Executive Compensation Survey Highlighting Key Trends and Regulatory Developments

Retrieved on: 
Thursday, December 7, 2023
Computer security, Shearman, Face, Woman, Research, Risk management, First Republic Bank, Disclosure, Artificial intelligence, Gender, Shearman & Sterling, AI, Signature Bank, Broad, Silicon Valley Bank, Climate change, Risk, Thought, Silicon, Corporate governance, SVB

NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Global law firm Shearman & Sterling today released its annual Corporate Governance & Executive Compensation Survey.

Key Points: 
  • NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Global law firm Shearman & Sterling today released its annual Corporate Governance & Executive Compensation Survey.
  • Now in its 21st edition, the survey provides a review of key corporate governance trends, along with a comprehensive examination of the corporate governance and executive compensation practices of 100 of the largest U.S. public companies.
  • The annual survey tracks the impact of changing practices, trends and regulatory developments on key areas of corporate governance and executive compensation.
  • Given the breadth of data collected by the survey, the report can serve as a benchmark for public company directors and executives to assess their governance practices.

Pluristyx Announces Major New Funding Round to Bolster Expansion Plans

Retrieved on: 
Thursday, December 21, 2023
Health, Stem Cells, Genetics, General Health, Research, Science, Biotechnology, IPSC, Broad, CGMP

Pluristyx, a leading provider of tools, technologies and services for the development of cell therapies, has today announced the closing of a major fundraising round led by BroadOak Capital Partners.

Key Points: 
  • Pluristyx, a leading provider of tools, technologies and services for the development of cell therapies, has today announced the closing of a major fundraising round led by BroadOak Capital Partners.
  • The oversubscribed funding round also featured participation from existing investors and key opinion leaders across the life sciences industry.
  • This infusion of capital enables Pluristyx to expand its existing cGMP cell line and service portfolio and broaden partner access to Pluristyx’s revolutionary panCELLa platform.
  • As part of the round, Pluristyx is pleased to announce the addition of two experienced life sciences executives, Bryan Poltilove and Jeffrey Allen, to the company as strategic advisors.

Bayer and Broad Institute of MIT and Harvard Extend Research Collaboration to Develop New Cancer Therapies

Retrieved on: 
Thursday, November 2, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, MIT, AACR, ESMO, Innovation Center station, HER2, European Society for Medical Oncology, Broad Institute, BRIC, American Society of Clinical Oncology, Harvard University, Society, Drug development, Drug discovery, Broad, Cancer, Drug resistance, American Association for Cancer Research, Patient, ASCO, EGFR, Pharmaceutical industry, Bayer, Kendall Square

Bayer and the Broad Institute of MIT and Harvard today announced that they have extended their research collaboration of 10 years by an additional five years, to develop and advance innovative cancer treatments.

Key Points: 
  • Bayer and the Broad Institute of MIT and Harvard today announced that they have extended their research collaboration of 10 years by an additional five years, to develop and advance innovative cancer treatments.
  • “Bayer’s established collaboration with the Broad Institute has already resulted in three clinical oncology candidates.
  • Bayer with its Bayer Research & Innovation Center (BRIC) is closely located to the Broad Institute in Kendall Square, Cambridge, MA.
  • BRIC houses a center of precision oncology research equipped with state-of-the-art laboratories for the development of targeted next-generation cancer therapies for patients.

Bayer and Broad Institute extend cancer therapy research collaboration

Retrieved on: 
Thursday, November 2, 2023
MIT, HER2, Broad Institute, Publication, Organization, Research, Harvard University, Drug development, Cancer, Broad, Patient, EGFR, Pharmaceutical industry, Bayer

CAMBRIDGE, Mass., Nov. 2, 2023 /PRNewswire/ -- Bayer and the Broad Institute of MIT and Harvard have renewed their research alliance, adding five years to a 10-year collaboration that has already yielded three clinical oncology candidates. This research collaboration is aimed at identifying cancer targets and exploring novel therapeutic approaches in oncology with the goal of bringing more medicines to patients.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 2, 2023 /PRNewswire/ -- Bayer and the Broad Institute of MIT and Harvard have renewed their research alliance, adding five years to a 10-year collaboration that has already yielded three clinical oncology candidates.
  • This research collaboration is aimed at identifying cancer targets and exploring novel therapeutic approaches in oncology with the goal of bringing more medicines to patients.
  • "Bayer's established collaboration with the Broad Institute has already resulted in three clinical oncology candidates over the past decade.
  • We look forward to continuing our work with renowned Broad scientists to advance additional innovative cancer targets into clinical development."

Dr. Marvin Caruthers Receives the Inaugural Merkin Prize in Biomedical Technology in a Ceremony at the Broad Institute of MIT and Harvard

Retrieved on: 
Wednesday, October 4, 2023
DNA, Boulder, Colorado, Broad Institute, University, Therapy, Biochemistry, Genetics, Public, Biomedical technology, Biomedical Research, Research, MIT, RNA, Harvard University, Messenger, Chemistry, Biology, Health, Broad, Vaccine, Pharmaceutical industry, Merkin

CAMBRIDGE, Mass., Oct. 4, 2023 /PRNewswire/ -- Dr. Richard Merkin, Founder and CEO of Heritage Provider Network, and members of the team at the Broad Institute of MIT and Harvard, awarded Dr. Marvin Caruthers, of the University of Boulder Colorado, the inaugural Richard Merkin Prize in Biomedical Technology in a daylong celebration and gala dinner recognizing Dr. Caruthers' groundbreaking work in synthesizing DNA.

Key Points: 
  • Dr. Caruthers won the inaugural Merkin Prize in Biomedical Technology for developing automated technology for quickly synthesizing DNA that provided essential elements in the development of modern molecular medicine.
  • "I'm so pleased and proud to honor Dr. Caruthers with the inaugural Merkin Prize in Biomedical Technology.
  • The biotech industry would not be what it is today if it weren't for Dr. Caruthers," Dr. Merkin said.
  • The prize was created by the Merkin Family Foundation and is administered by the Broad Institute of MIT and Harvard.

FYR DIAGNOSTICS WELCOMES DR. NIALL LENNON AND DR. RYAN WALTERS TO ITS SCIENTIFIC ADVISORY BOARD

Retrieved on: 
Wednesday, August 23, 2023
SAB, Broad Institute, EV, Genomics, NGS, FYR, Liquid biopsy, Cancer, United States Air Force Scientific Advisory Board, Research, MIT, Harvard University, Associate, Cancer Diagnostic Probe, EVS, Seminal vesicles, CRSP, Management, Knowledge, Diagnosis, Translational Genomics Research Institute, Massive parallel sequencing, Broad, Medical device

MISSOULA, Mont., Aug. 23, 2023 /PRNewswire/ -- FYR Diagnostics , an emerging company developing liquid biopsy technologies for the diagnosis of cancer and neurodegenerative diseases, is pleased to welcome Dr. Niall Lennon and Dr. Ryan Walters to its Scientific Advisory Board (SAB).

Key Points: 
  • MISSOULA, Mont., Aug. 23, 2023 /PRNewswire/ -- FYR Diagnostics , an emerging company developing liquid biopsy technologies for the diagnosis of cancer and neurodegenerative diseases, is pleased to welcome Dr. Niall Lennon and Dr. Ryan Walters to its Scientific Advisory Board (SAB).
  • Renowned for his pivotal contributions in the fields of genomics and diagnostics, Dr. Lennon will offer valuable insights into FYR Dx's innovative use of Extracellular Vesicles (EVs) in clinical diagnostics.
  • Dr. Lennon is currently the Senior Director of Translational Genomics at the Broad Institute of MIT and Harvard.
  • Speaking to the newest additions to the team, Dr. Chris Booth, CEO of FYR Diagnostics, stated, "We are excited to welcome Dr. Lennon and Dr. Walters to our SAB.